S&P Futures
4,031.25 +30.00 (+0.75%) Dow Futures
32,674.00 +240.00 (+0.74%) Nasdaq Futures
12,945.50 +55.25 (+0.43%) Russell 2000 Futures
1,770.60 +22.90 (+1.31%) Crude Oil
70.08 +0.82 (+1.18%) Gold
1,953.50 -30.30 (-1.53%)
Delcath Systems Inc (DV3R.F)
- PR Newswire
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology businesses, most recently serving as Chief Executive Officer of both Curium's SPECT and International business units. In a
- PR Newswire
Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the treatment of patients with unresectable hepatic-dominant metastatic ocular melanoma (mOM).
- PR Newswire
Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16.
